Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease

Drug Discoveries & Therapeutics
Yohei OnoMasahiko Kurabayashi

Abstract

The effectiveness of long-term administration of tolvaptan in heart failure (HF) patients with chronic kidney disease (CKD) has not been fully studied. Hence, in this study, we investigated the effects of chronic administration of tolvaptan on patients with HF and CKD. We consecutively enrolled 31 patients with acute HF syndrome (AHFS) who were administrated tolvaptan as a long-term medication (TLV group). All patients had a history of prior HF admission and CKD. We also consecutively enrolled 27 patients with AHFS, a prior history of HF and CKD (conventional group). We compared renal function and outcomes between the two groups at discharge for AHFS and after 6 months of follow-up. The estimate glomerular filtration rate (eGFR) was maintained at approximately the same level in the TLV group exhibited approximately the same eGFR (-1.1 ± 8.3 mL/min/1.73 m2) but decreased in the conventional group (-7.4 ± 10.4 mL/min/1.73 m2). There was a significant difference in the changes observed in eGFR between the conventional and TLV groups (p = 0.01). There were no significant differences in the frequencies of rehospitalization and death. Long-term administration of tolvaptan may prevent increased renal dysfunction in HF patients with CK...Continue Reading

References

Nov 27, 1978·European Journal of Clinical Pharmacology·F KrückB Kaufmann
Jul 19, 2003·News in Physiological Sciences : an International Journal of Physiology Produced Jointly by the International Union of Physiological Sciences and the American Physiological Society·Volker Vallon
Aug 23, 2003·Journal of the American College of Cardiology·Michael DomanskiUNKNOWN Studies of Left Ventricular Dysfunction
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Sep 29, 2005·American Journal of Physiology. Renal Physiology·Lisa C Costello-BoerrigterJohn C Burnett
Jun 13, 2006·The American Journal of Cardiology·Shervin EshaghianGregg C Fonarow
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Aug 28, 2007·European Journal of Heart Failure·Vic HasselbladKirkwood F Adams
Apr 19, 2008·Internal Medicine·Kunitoshi Iseki
Feb 14, 2009·Journal of the American College of Cardiology·Wilfried MullensW H Wilson Tang
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
Aug 10, 2010·American Heart Journal·Husam M Abdel-QadirDouglas S Lee
Nov 29, 2011·Cardiovascular Drugs and Therapy·Toshiyuki OnogawaYoshitaka Yamamura
Jun 8, 2012·Journal of Cardiovascular Medicine·Muthiah VaduganathanUNKNOWN EVEREST investigators
Mar 29, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Koichiro KinugawaKazuki Mizuguchi
Jan 23, 2016·Clinical Kidney Journal·Baris AfsarMehmet Kanbay
Jun 20, 2017·Drug Discoveries & Therapeutics·Shunsuke KiuchiTakanori Ikeda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.